Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Current Deferred Revenue (2020 - 2022)

Neuroone Medical Technologies' Current Deferred Revenue history spans 3 years, with the latest figure at $1.5 million for Q3 2022.

  • For Q3 2022, Current Deferred Revenue rose 16777.62% year-over-year to $1.5 million; the TTM value through Sep 2022 reached $1.5 million, up 16777.62%, while the annual FY2022 figure was $1.5 million, 16777.62% up from the prior year.
  • Current Deferred Revenue reached $1.5 million in Q3 2022 per NMTC's latest filing, up from $2248.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $1.5 million in Q3 2022 to a low of $2248.0 in Q4 2021.
  • Average Current Deferred Revenue over 3 years is $195794.6, with a median of $11109.0 recorded in 2021.
  • Peak YoY movement for Current Deferred Revenue: crashed 95.61% in 2021, then surged 16777.62% in 2022.
  • A 3-year view of Current Deferred Revenue shows it stood at $51160.0 in 2020, then plummeted by 95.61% to $2248.0 in 2021, then skyrocketed by 64632.56% to $1.5 million in 2022.
  • Per Business Quant, the three most recent readings for NMTC's Current Deferred Revenue are $1.5 million (Q3 2022), $2248.0 (Q2 2022), and $2248.0 (Q1 2022).